Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials
PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites.
'We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit,' said SCRI chief information and digital officer Yazhene Krishnaraj. 'This strategic collaboration empowers our clinical teams to deliver groundbreaking therapies to patients with enhanced precision and speed.'
Veeva Clinical Platform will enable SCRI to simplify and standardize trial processes and information flow, improving how investigators and clinical teams work together and share data. With a connected foundation for clinical research, SCRI will be able to automate key processes and provide a streamlined experience for its sites.
'We're excited to work closely with SCRI to drive innovation in oncology research,' said Jim Reilly, president of Veeva Development Cloud. 'In a first-of-a-kind partnership, Veeva Clinical Platform will serve as SCRI's clinical trial foundation for its CRO and SMO. By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials.'
About Veeva Clinical Platform
Veeva Clinical Platform is a complete and connected platform across clinical operations and data applications. This end-to-end platform includes CTMS, EDC, clinical workbench (CDB), RTSM, eCOA, eTMF, Site Connect, Study Training, and more. Connected products streamline clinical trials from study start-up to close and automate a connected data flow. To learn more about Veeva Clinical Platform, visit veeva.com/VeevaClinicalPlatform.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Visit SCRI.com to learn more.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's strategic collaboration with SCRI and the expected results or benefits from such collaboration. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
View original content to download multimedia: https://www.prnewswire.com/news-releases/veeva-and-sarah-cannon-research-institute-form-strategic-collaboration-to-advance-oncology-clinical-trials-302472592.html
SOURCE Veeva Systems
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The Smartest Dividend Stock to Buy With $1,000 Right Now
Key Points Dividend stocks that reliably increase their dividends are the perfect pick for income investors. Buying reliable dividend stocks when they have historically high yields is ideal. Universal Health Realty Income Trust's 7.4% dividend yield is near the highest levels of the past decade. 10 stocks we like better than Johnson & Johnson › If you are a dividend investor looking to maximize the income your portfolio generates, you will want to do a deep dive on Universal Health Realty Income Trust (NYSE: UHT). It has a historically high 7.4% dividend yield and a great track record of dividend growth to back it up. The dividend stock won't be right for every income investor, but for a select few it could be the smartest dividend stock to buy right now. What makes a dividend stock attractive? One of the first things that income investors look for is dividend yield. Universal Health Realty Income Trust has that factor pegged, with a huge 7.4% dividend yield. But some reference points will help. The S&P 500 (SNPINDEX: ^GSPC) has an itty bitty yield of 1.3%. The average healthcare stock has a yield of 1.8%. And the average real estate investment trust (REIT) has a yield of roughly 4.1%. Very clearly, Universal Health Realty is more attractive on the yield front. But yield has to be considered along with reliability. For example, one of the most reliable dividend-paying healthcare stocks is Johnson & Johnson (NYSE: JNJ), with 63 years of annual dividend hikes behind it. Next up is Becton, Dickinson (NYSE: BDX), with 53 years of hikes. Those two companies are Dividend Kings, an elite status that Universal Health Realty simply can't claim. That said, Johnson & Johnson's yield is 3.4% and Becton, Dickinson's yield is an even smaller 2.4%. Universal Health Realty's dividend has been hiked annually for four decades. That's a pretty good streak, even though it isn't yet a Dividend King, when you add in the real estate investment trust's huge yield. A $1,000 investment will get you around 24 shares of the healthcare-focused REIT. Universal Health Realty Trust is for income right now So a lofty yield and a strong dividend history make Universal Health Realty Trust attractive. It is extra attractive right now because the yield is near the highest levels of the past decade, suggesting the stock is on the sale rack. But there's just one small problem: Dividend growth has never been a big selling point here. As the chart above highlights, both JNJ's and Becton, Dickinson's dividend growth has been far superior to that of Universal Health Realty Trust. The goal for Universal Health Realty Trust isn't rapid dividend growth, it is reliable growth. It is a slow and steady tortoise, and that is likely all it will ever be. And that brings up the second big issue that investors need to know about. Universal Health Realty Trust is externally managed by Universal Health Services (NYSE: UHS), the REIT's largest tenant. There are very clear issues with conflicts of interest that have to be considered. However, the 40-year track record of slow and steady dividend growth is an indication of what Universal Health Services is doing here. More attractive than it was, not for all, but smart for some The interesting thing here is that prior to the coronavirus pandemic, Universal Health Realty's dividend yield was a tiny 2.1% or so. At that point, investors were way too optimistic about the REIT given the tortoise-like nature of the dividend. But, today, with the yield at 7.4%, this healthcare stock is a lot more attractive. It won't be right for every dividend investor, given the management structure and that tortoise-like dividend growth. For dividend growth investors, JNJ or Becton, Dickinson will be more appropriate. However, if you are trying to maximize the income you generate from your portfolio today and you are looking for a healthcare investment, Universal Health Realty Trust could be perfect for your portfolio if you have $1,000 or $10,000 to invest. Should you invest $1,000 in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. The Smartest Dividend Stock to Buy With $1,000 Right Now was originally published by The Motley Fool Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
2 hours ago
- Yahoo
3 Dividend Stocks to Hold for the Next 10 Years
Key Points American Express gets money from its card and also by providing loans. Coca-Cola's global footprint is a strength. McDonald's is the world's top fast-food franchise and plans to open 2,200 new locations this year. 10 stocks we like better than Coca-Cola › I've always appreciated dividend stocks as a solid strategy for any investment portfolio. While I recognize the importance of growth stocks (and hold several of them), stocks that represent companies that pay a solid, consistent dividend also are an important tool for growing wealth. The best thing about dividend stocks is that they're ideal for all types of investors. If you're just starting out or a few years into building your portfolio, dividends are a great way to turbocharge your savings. In addition to the gains you get when the stock price rises, you can take the quarterly dividend payout and reinvest it, adding to your positions and growing wealth more quickly. If you're in retirement and starting to draw down your investments, dividend stocks are an ideal way to keep the income flowing. Many investors in retirement use dividend payouts to pay for living expenses, which keeps them from drawing down their retirement funds too quickly. There are hundreds of dividend stocks from which to choose, but I prefer ones from established companies that provide consistent payouts. Here are three that are worth considering today. 1. Coca-Cola I like Coca-Cola (NYSE: KO) because it has a dominant position in the beverage industry, holding the No. 1 position in 2024 with a 48% market share, according to Statista. And there's plenty to drink aside from the famous Cola-Cola carbonated beverage. The company also sells bottled water, sports drinks, tea, juices and a line of alcoholic beverages. In all, the company has 30 brands that are each valued at a minimum of $1 billion. Revenue in the first quarter declined 2% to $11.1 billion because of slumping sales in North America. But Coca-Cola was able to mitigate losses by increasing sales in China, India, and Brazil -- and the company's global footprint will continue to be a hedge against weakness in any one geographic area. Net income attributable to shareholders as $3.33 billion and $0.77 per share, up from $3.18 and $0.74 per share in the first quarter of 2024. Coca-Cola also offers a strong dividend yield of 2.9%. 2. American Express Like Coca-Cola, American Express (NYSE: AXP) is a favored dividend stock held by Warren Buffett in Berkshire Hathaway's portfolio. Berkshire currently has a dominant 21.6% stake in American Express, holding 151.6 million shares. American Express stands out from other credit card companies because it caters to a more affluent base, with a stronger emphasis on its gold and platinum cards, as well as corporate accounts. As an American Express customer, I can attest that the travel perks are extremely generous. But American Express also is different in how it makes money. Not only does it issue cards like Visa and Mastercard, but it operates its own payment network that allows it to extend credit and earn income from the interest it charges on loans. Revenue in the first quarter was $2.6 billion and $3.64 per share, up from $2.4 billion and $3.33 billion in the same quarter of 2024. American Express also has a dividend yield of 1%. 3. McDonald's McDonald's (NYSE: MCD) is the dominant fast-food chain in the world, boasting more than 43,000 locations in over 100 countries. From its start as a single restaurant in California, McDonald's revolutionized the industry with its consistent standards and franchise model. After a customer backlash last year over higher prices and inflation, McDonald's has been aggressive in pushing value menus and deals, including the return of its chicken snack wraps this spring. It's also driving traffic through its loyalty program, which includes 175 million customers who are active at least every 90 days within 60 global markets. McDonald's attributes $30 billion in overall sales to its loyalty membership program. Global sales were down 0.1% in 2024, and that trend continued in the first quarter of 2025, as global sales dropped 0.1% from a year ago. In the U.S., sales were down 3.6% from a year ago, and earnings per share of $2.60 was down 2% from a year ago. However, McDonald's still plans to open 2,200 new locations in 2025, which it says will boost its global sales growth by more than 2% this year. With its 2.4% dividend yield, McDonald's is a quality dividend stock for a long-term investor. Should you buy stock in Coca-Cola right now? Before you buy stock in Coca-Cola, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Coca-Cola wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 American Express is an advertising partner of Motley Fool Money. Patrick Sanders has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Mastercard, and Visa. The Motley Fool has a disclosure policy. 3 Dividend Stocks to Hold for the Next 10 Years was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
1 Stock That Turned $1,000 Into $66,000
Key Points This company does today what it did exactly 30 years ago, but with a much bigger presence that supports higher sales and profits. Demand from households isn't robust today due to unfavorable macroeconomic conditions, but industry tailwinds should support durable growth over time. Its shares trade at a valuation that's in line with the market average. 10 stocks we like better than Home Depot › Investing works best when investors adopt a long-term mindset. Thinking in terms of decades instead of days or months allows one to focus on the factors that matter the most. And it allows for the power of compound growth to work its magic. Looking back, there have been some massive winners that favored patient investors. For example, one dominant industry-leading enterprise has generated a total return of 6,540% for shareholders over the past 30 years (as of July 15). That monster gain means that if someone invested just $1,000 in July 1995, held on, and reinvested their dividends steadily, their holding would be worth about $66,000 today. But what retail stock produced this 66-fold return, and is it still a worthwhile portfolio addition today? A history of success Chances are that you live close to a Home Depot (NYSE: HD) location. The company now has stores within 10 miles of 90% of the U.S. population. But it wasn't always this way. Back in January 1995, there were only 340 Home Depot locations. The company was growing like wildfire in those days, as it sold building materials, appliances, home decor, and various tools to both do-it-yourselfers and professional customers. The early leadership team knew that they could expand, opening new stores in new markets. As of May 4, 2025, there were 2,350 Home Depot locations, including 182 in Canada and 140 in Mexico. The business is a true retailing juggernaut these days, with $39.9 billion in sales in its fiscal Q1 alone. Unsurprisingly, this top-line figure is astronomically higher than what it booked 30 years prior. And it makes Home Depot the leader in the home improvement retail space, with Lowe's running a distant second. Home Depot also generates tremendous profits. It reported $5.1 billion in operating income in its most recent fiscal quarter. Management is keen to return money to its shareholders. Dividend payouts totaled $8.9 billion in its fiscal 2024, and share repurchases were also a part of the mix. Is Home Depot stock a buy now? Home Depot's rise in the past three decades has been impressive. It's a dominant retailer with a strong brand presence, unmatched inventory assortment, and well-developed omnichannel capabilities. This should help it maintain its industry position. But is the stock a buy now? One reason investors might not think so is that the company hasn't been performing as well in recent years. Home Depot has shown just how sensitive it is to macroeconomic factors such as higher interest rates and inflationary pressures that discourage consumers from spending big money on renovation projects and upgrades. Home Depot is positioned well to thrive when macro conditions improve, though. One data point to keep in mind is that in 2022, the median age of a home in the U.S. was 40 years, up from 31 years in 2005. Older houses require more upkeep, which should support demand for what Home Depot sells. This is a high-quality company that has hit a rough patch. Yet the stock still trades at a price-to-earnings ratio of 24.3. That's close to the ratio that S&P 500 trades at, but it's still an expensive valuation considering that Home Depot's earnings per share are only projected to grow at a compound annual rate of 5.9% between fiscal 2024 and fiscal 2027, according to analysts' consensus estimates. The positive view is that the home improvement industry will always be around, and that durability might be an attractive trait for investors looking to buy shares and hold them for the long haul. In my opinion, however, the best course of action would be to keep Home Depot on your watch list and wait for a lower valuation. Should you invest $1,000 in Home Depot right now? Before you buy stock in Home Depot, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Home Depot wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Home Depot. The Motley Fool recommends Lowe's Companies. The Motley Fool has a disclosure policy. 1 Stock That Turned $1,000 Into $66,000 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
